Principal Investigator
Gilberto Lopes
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231267
Clinical Trial Summary
A Phase 1 Study Investigating the Safety, Tolerability,
Pharmacokinetics, and Preliminary Antitumor Activity of HPK1
Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1
Monoclonal Antibody Tislelizumab in Patients with Advanced
Solid Tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
+1 (954) 8177628